JP2016516068A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516068A5
JP2016516068A5 JP2016503207A JP2016503207A JP2016516068A5 JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5 JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5
Authority
JP
Japan
Prior art keywords
substituted
group
unsubstituted
aryl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503207A
Other languages
English (en)
Japanese (ja)
Other versions
JP6572201B2 (ja
JP2016516068A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029723 external-priority patent/WO2014145068A1/en
Publication of JP2016516068A publication Critical patent/JP2016516068A/ja
Publication of JP2016516068A5 publication Critical patent/JP2016516068A5/ja
Application granted granted Critical
Publication of JP6572201B2 publication Critical patent/JP6572201B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503207A 2013-03-15 2014-03-14 眼疾患を処置するための組成物、製剤、および方法 Active JP6572201B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361792868P 2013-03-15 2013-03-15
US201361792679P 2013-03-15 2013-03-15
US61/792,679 2013-03-15
US61/792,868 2013-03-15
US201361882056P 2013-09-25 2013-09-25
US201361882048P 2013-09-25 2013-09-25
US61/882,048 2013-09-25
US61/882,056 2013-09-25
US201461934570P 2014-01-31 2014-01-31
US61/934,570 2014-01-31
PCT/US2014/029723 WO2014145068A1 (en) 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019147238A Division JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法

Publications (3)

Publication Number Publication Date
JP2016516068A JP2016516068A (ja) 2016-06-02
JP2016516068A5 true JP2016516068A5 (enExample) 2017-04-20
JP6572201B2 JP6572201B2 (ja) 2019-09-04

Family

ID=51529957

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503207A Active JP6572201B2 (ja) 2013-03-15 2014-03-14 眼疾患を処置するための組成物、製剤、および方法
JP2019147238A Active JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法
JP2021064106A Active JP7249374B2 (ja) 2013-03-15 2021-04-05 眼疾患を処置するための組成物、製剤、および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019147238A Active JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法
JP2021064106A Active JP7249374B2 (ja) 2013-03-15 2021-04-05 眼疾患を処置するための組成物、製剤、および方法

Country Status (17)

Country Link
US (10) US9440963B2 (enExample)
EP (3) EP2967066B1 (enExample)
JP (3) JP6572201B2 (enExample)
KR (1) KR20150129019A (enExample)
CN (2) CN109925312A (enExample)
AU (2) AU2014233363B2 (enExample)
BR (1) BR112015023753A2 (enExample)
CA (1) CA2903871A1 (enExample)
ES (2) ES2928162T3 (enExample)
GB (3) GB2549865B (enExample)
HK (2) HK1219836A1 (enExample)
IL (2) IL240786B (enExample)
MX (1) MX371382B (enExample)
MY (1) MY171945A (enExample)
PH (2) PH12015502153B1 (enExample)
SG (1) SG11201507131WA (enExample)
WO (1) WO2014145068A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
DK2493457T3 (en) 2009-10-30 2017-10-02 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
US20180092883A1 (en) * 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
JP6151186B2 (ja) 2010-12-08 2017-06-21 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 創傷滲出液システム付属装置
CN103347561B (zh) 2010-12-08 2016-09-07 康沃特克科技公司 用于评估伤口分泌液的集成系统
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
KR20150063567A (ko) * 2012-10-11 2015-06-09 아이엑스 바이오파마 리미티드 고형 제형
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) * 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
ES2894802T3 (es) * 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
WO2017075814A1 (zh) * 2015-11-06 2017-05-11 华为技术有限公司 一种语音漫游方法，移动性管理网元及接入网网元
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
CA3137138A1 (en) * 2019-04-18 2020-10-22 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of tie-2
EP3962482A4 (en) * 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
WO2021086904A1 (en) 2019-10-29 2021-05-06 Aerpio Pharmaceuticals, Inc. Small molecule activators of tie-2
CN117460743A (zh) * 2020-06-16 2024-01-26 曼宁研究公司 小分子ve-ptp抑制剂
CA3202338A1 (en) * 2020-12-18 2022-06-23 EyePoint Pharmaceuticals, Inc. Methods for manufacture of small molecule activators of tie-2
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025128706A1 (en) * 2023-12-11 2025-06-19 Massachusetts Eye And Ear Infirmary Methods of using tie-2 activators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
JP4122056B2 (ja) 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド Ｔｉｅ−２リガンド、その作製方法および使用方法
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6455031B1 (en) * 1997-06-18 2002-09-24 David G Davies Methods and compositions for controlling biofilm development
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
ATE241380T1 (de) 1999-03-26 2003-06-15 Regeneron Pharma Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
AU784231B2 (en) 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
US7166435B2 (en) * 2001-08-06 2007-01-23 The Quigley Corporation Compositions and methods for reducing the transmissivity of illnesses
US20030158199A1 (en) * 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7091193B2 (en) * 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤
US8178570B2 (en) * 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
EP1756158A1 (en) * 2004-06-02 2007-02-28 Valtion Teknillinen Tutkimuskeskus Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
EA016227B1 (ru) 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Способ лечения офтальмологических неоваскулярных расстройств
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
NZ570381A (en) * 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US8846685B2 (en) * 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008027013A2 (en) * 2006-08-29 2008-03-06 National Cancer Centre Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
ES2612258T3 (es) 2006-10-27 2017-05-16 Sunnybrook Health Sciences Center Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis
DK1932558T3 (da) 2006-12-13 2011-09-05 Shl Group Ab Autoinjektor
CN101678170B (zh) 2007-03-23 2012-05-30 Shl集团有限责任公司 自动注射器
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
DK2162170T3 (da) 2007-07-06 2011-06-14 Shl Group Ab Enkeltskudsinjektionssprøjte med dobbeltfjedre
WO2009037141A1 (en) 2007-09-18 2009-03-26 Shl Group Ab Automatic injection device with needle insertion
US9320770B2 (en) * 2008-03-31 2016-04-26 Shiseido Company, Ltd. Blood vessel maturation, normalization or stabilization agent and wrinkle preventer/improver
CN102099069B (zh) 2008-05-20 2013-11-27 Shl集团有限责任公司 用于药物输送装置的装置
US8075517B2 (en) 2008-06-11 2011-12-13 Shl Group Ab Medicament delivery device
ES2536418T3 (es) * 2008-06-18 2015-05-25 Shiseido Company, Ltd. Estabilizador de vasos linfáticos
JP4751482B2 (ja) * 2008-07-22 2011-08-17 株式会社メニコン コンタクトレンズ用液剤
EP2378609A1 (en) 2008-12-22 2011-10-19 Fujikura, Ltd. Film antenna and method for manufacturing the same
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
DK2385763T3 (en) * 2009-01-12 2018-07-16 Aerpio Therapeutics Inc METHODS OF TREATING VASCULAR LEAK SYNDROME
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
TWI393578B (zh) 2009-07-07 2013-04-21 Shl Group Ab 注射裝置
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
JP2011201811A (ja) * 2010-03-25 2011-10-13 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
US20110319455A1 (en) 2010-04-19 2011-12-29 Bruce Steven Klein Antifungal Treatment
CA2797247C (en) * 2010-04-28 2019-10-22 Sunnybrook Health Sciences Centre Methods and uses of tie2 binding and/or activating agents
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
NZ610230A (en) 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
EP2647385A4 (en) * 2010-12-02 2014-04-30 Maruzen Pharm Co Ltd TIE2 ACTIVATOR, VASCULAR ENDOTHELIAL CELL GROWTH FACTOR (VEGF), ANTI-ANGIOGENESIS AGENT, MEANS FOR REINFORCING BLOOD VESSELS, MEANS FOR THE NORMALIZATION OF BLOOD VESSELS, DEVICES FOR STABILIZING BLOOD VESSELS AND PHARMACEUTICAL COMPOSITION
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
JP2014508749A (ja) 2011-02-11 2014-04-10 サイヴィーダ ユーエス，インコーポレイテッド 抗浮腫治療薬を使用する黄斑浮腫の治療方法
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system

Similar Documents

Publication Publication Date Title
JP2016516068A5 (enExample)
JP2018528273A5 (enExample)
JP6968921B2 (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
JP2018518537A5 (enExample)
JP2015503635A (ja) フマギリン誘導体ｐｈｆ複合体の医薬品配合物
AU2014273983A1 (en) Cyclodextrin-based polymers for the therapeutic delivery
JP2010524963A5 (enExample)
EP1613356A1 (en) A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxy acid
JP2015071624A (ja) 治療的送達のためのシクロデキストリンに基づく重合体
RU2015143898A (ru) Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза
CN111344018B (zh) 聚乙二醇化卡非佐米化合物的稳定的组合物
JP2019511497A5 (enExample)
US20220226444A1 (en) Formulations of fosaprepitant and aprepitant
JP2017506640A5 (enExample)
JP2024112842A (ja) Ｍｃｌ１タンパク質を阻害する化合物を投与するための製剤及び投与量
US10660906B2 (en) Hyaluronan conjugates with pharmaceutically active substances, methods and compositions
JP2020526497A (ja) 合成バイオコンジュゲート
CN110876259A (zh) 注射用组合物
US20070049552A1 (en) Fluoroquinolone formulations and methods of making and using the same
JP2013532664A5 (enExample)
JP2018536650A5 (enExample)
US20130196946A1 (en) Cyclodextrin-based polymers for therapeutic delivery
ES2749053T3 (es) Polimixinas de baja sustitución y sus composiciones
US20210228577A1 (en) Substituted cyclodextrin-metal complexes and uses thereof
CN105267214B (zh) N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用